Contact us

877-469-1TRM
424-208-8866

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)

Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy

For more information, please visit ClinicalTrials.gov

Patient Population Investigational Product(s) Phase Status
2nd or 3rd Line NSCLC U3-1287 (AMG 888) III Open and Accruing